Skip to content
OpenCapital
Get started

Immix Biopharma, Inc. IMMX Q2 2025 earnings

Reported August 8, 2025 · Before market open

EPS-$0.22Miss by $0.01
EPS estimate-$0.21

Next report

Aug 14, 2026 (In 2 weeks)
EPS estimate-$0.17

Financials

Q2 2025

Income statement

See full
Operating income-$6.7M-42.9%
Net income-$6.6M-50.8%
EPS (diluted)-$0.22-46.7%

Balance sheet

See full
Cash & equivalents$11.6M-51.5%
Total debt$1.0M-4.4%
Total equity$4.7M-80.5%
Total assets$15.6M-45.8%

Cash flow

See full
Operating cash flow-$5.3M-1.0%
CapEx$127.6K+31.5%
Free cash flow-$5.4M-1.6%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$62.45M+9.6%
Enterprise value$51.85M+52.0%

Returns & leverage

See full
Return on equity-162%+225pp
Debt / equity0.2×+0.2×
Current ratio1.2×-5.8×

Versus estimates

Revenue

Q4 2024$96.3K

Diluted EPS

Q1 2026-$0.18Beat by $0.00Q3 2025-$0.24Miss by $0.05
Q2 2025-$0.22Miss by $0.01
Q1 2025-$0.15Beat by $0.08Q4 2024-$0.16Beat by $0.09Q3 2024-$0.24Miss by $0.08

Ask the moment Immix Biopharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Immix Biopharma, Inc. report Q2 2025 earnings?
Immix Biopharma, Inc. (IMMX) reported Q2 2025 earnings on August 8, 2025 before market open.
What were Immix Biopharma, Inc.'s Q2 2025 revenue and EPS?
Immix Biopharma, Inc. reported eps of $-0.22 for Q2 2025.
Did Immix Biopharma, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.21 by $0.01.
How did Immix Biopharma, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 46.7% from $-0.15.
Where can I find Immix Biopharma, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001641172-25-022829) directly on SEC EDGAR. The filing index links above go to sec.gov.